Kiniksa Pharmaceuticals International (KNSA) P/E ratio
Kiniksa Pharmaceuticals International (KNSA) trades at 72.1× its earnings per share over the last twelve months. At the end of fiscal 2025 (December 31, 2025) its P/E ratio was 55.0×. Today's figure is 31.0% above the fiscal 2025 year-end. Figures as of 18 Nov 2026, 10:43 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- P/E ratio today
- 72.1×
- P/E ratio, fiscal 2025
- 55.0×
- Highest on record
- 87.7×fiscal 2023
- Lowest on record
- 5.8×fiscal 2022
- Fiscal years on record
- 32022–2025
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.
Kiniksa Pharmaceuticals International P/E ratio, in more detail
Across the 3 fiscal year-ends on record (2022–2025), the highest was 87.7× in fiscal 2023 and the lowest 5.8× in fiscal 2022. Today's P/E ratio is higher than at 67% of the 3 fiscal year-ends on record; their median is 55.0×.
P/E ratio at each fiscal year-end
The last point is today's figure; the others are fiscal year-ends.
Kiniksa Pharmaceuticals International P/E ratio, year by year
| Fiscal year | P/E ratio | Change | Year ended | Share price at year-end | Diluted EPS |
|---|---|---|---|---|---|
| Today | 72.1× | — | $95.11 | — | |
| 2025 | 55.0× | — | $41.25 | $0.75 | |
| 2024 | — | — | $19.78 | -$0.60 | |
| 2023 | 87.7× | 1,422.2% up | $17.54 | $0.20 | |
| 2022 | 5.8× | — | $14.98 | $2.60 | |
| 2021 | — | — | $11.77 | -$2.30 | |
| 2020 | — | — | $17.67 | -$2.61 | |
| 2019 | — | — | $11.06 | -$2.99 | |
| 2018 | — | — | $28.09 | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
The P/E ratio is the share price divided by earnings per share: for past years this page divides the closing price for the month each fiscal year ended in by that year's diluted earnings per share, and a year with a loss has no P/E.
How to read it
It is the number of years of current profit the price pays for — a high figure means investors expect growth, and it is best judged against the company's own history.
Kiniksa Pharmaceuticals International, figure by figure
- Kiniksa Pharmaceuticals International market cap
- Kiniksa Pharmaceuticals International revenue
- Kiniksa Pharmaceuticals International earnings
- Kiniksa Pharmaceuticals International earnings per share (EPS)
- Kiniksa Pharmaceuticals International P/S ratio
- Kiniksa Pharmaceuticals International P/B ratio
- Kiniksa Pharmaceuticals International free cash flow
- Kiniksa Pharmaceuticals International operating margin
- Kiniksa Pharmaceuticals International dividend
- Kiniksa Pharmaceuticals International shares outstanding
- Kiniksa Pharmaceuticals International total debt
- Kiniksa Pharmaceuticals International cash on hand
- Kiniksa Pharmaceuticals International total assets
- Kiniksa Pharmaceuticals International return on equity (ROE)
- Kiniksa Pharmaceuticals International return on invested capital (ROIC)
Kiniksa Pharmaceuticals International (KNSA) overview: price, valuation and scorecardAll health care companies by market value
Kiniksa Pharmaceuticals International P/E ratio: questions and answers
What is Kiniksa Pharmaceuticals International's P/E ratio?
Kiniksa Pharmaceuticals International (KNSA) trades at 72.1× its earnings per share over the last twelve months. At the end of fiscal 2025 (December 31, 2025) its P/E ratio was 55.0×.
Is Kiniksa Pharmaceuticals International's P/E ratio high or low compared with its own history?
Today's P/E ratio is higher than at 67% of the 3 fiscal year-ends on record; their median is 55.0×.
What are the highest and lowest P/E ratio figures on record for Kiniksa Pharmaceuticals International?
Across the 3 fiscal year-ends on record (2022–2025), the highest was 87.7× in fiscal 2023 and the lowest 5.8× in fiscal 2022.
How is Kiniksa Pharmaceuticals International's P/E ratio calculated?
The P/E ratio is the share price divided by earnings per share: for past years this page divides the closing price for the month each fiscal year ended in by that year's diluted earnings per share, and a year with a loss has no P/E. For Kiniksa Pharmaceuticals International it is on record here for 3 fiscal years, 2022 to 2025.
Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.
Learn: P/E ratio
All stocks guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- PEG ratio: P/E adjusted for growth, and its limits
The PEG ratio is a stock's P/E divided by its expected yearly earnings growth in percent. A P/E of 20 with 10% expected growth gives a PEG of 2; with 20% growth, a PEG of 1. A PEG near 1 is the traditional rough mark of a fair price, but the growth figure is a forecast and often wrong.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
Cite this page
Funkfolio, “Kiniksa Pharmaceuticals International (KNSA) P/E ratio”, data as of 18 November 2026. https://funkfolio.com/stock/KNSA/pe-ratio
Underlying data: the company's filings with the SEC and Yahoo Finance.